Hi,
I am Katharina,
an independent Health Economics Consultant for innovative health technologies in the Netherlands.
As health economics expert, I help you with insights on your innovation for market access.
In health economics, we utilize mathematical models to estimate the health benefit of a health technology and the associated costs compared to what’s currently available to patients. Based on health economic principles, the strengths and weaknesses of the technology can be identified.
Does your technology perform better than your competitors? That’s a big plus! What about the costs? Are they higher, and if so, how much better does your health technology have to perform to balance out those extra costs? If you don’t know the answer yet, let’s get together and see how we can get that information.
I can help you with questions on…
Pricing strategies
What is the potential monetary value of my technology given its expected health benefits?
What is the potential maximum benefit I could achieve with my health technology in its field of application?
Where in the treatment line should I focus my health technology?
Reimbursement
I was asked to provide a budget impact analysis/ cost-effectiveness analysis for my health technology. What do I need to do? How can I provide this?
What health economics data do I need to collect in my study for reimbursement?
What do I need to do to get my technology reimbursed?
Investor readiness
We conducted a study and want to know whether the new technology could be reimbursed.
Does my health innovation have a potential monetary benefit? And if so, what is the magnitude?
Do you have a different question regarding your health technology? Reach out to find out what is needed to answer your questions.
Another client tested in a study whether their digital health innovation would improve the health condition of cancer survivors. In addition to clinical effectiveness, data on healthcare resource consumption such as specialist & GP visits, medicine use, and care provided by the government and family, was collected. Estimating the difference in costs between the innovation and the current care on population level, informed the client on the next steps of reimbursement & their investment strategy.
A client was interested in the monetary value of their health innovation for ulcerative colitis compared to the current treatments. Since they were early in the development, the clinical pathway of three different patient populations could be modelled. Based on the early cost-effectiveness analysis, the client could be informed on the population(s) with the highest monetary value to guide their next steps in the product development.
Examples from previous clients
For this client, an early cost-effectiveness model was build. They were so early in their technology development, that the potential health benefit needed to be based mainly on expert input. The technology had not been officially tested yet, but they client needed to know which patient population would benefit most and whether certain ways of administration would result in higher costs and/or lower health benefit. Additionally, the analysis helped the client understand how much better their innovation had to perform compared to the current technologies, and informed the client on the maximum reimbursement price possible given expected performance.
Another client, familiar with the reimbursement landscape, requested a cost-effectiveness analysis for their medical device for the Dutch setting. They weren’t sure yet which of the two patient population would benefit most from their medical device, so both were evaluated. Following the health economic guidelines for the Dutch setting, a cost-effectiveness model was developed. In cases where a technology has been researched extensively, as it was the case with this medical devices, literature can be used to populate the mathematical model. The resulting cost and health benefit trade-off for each of the two patient populations guided the client in their strategic choice for which population to apply for reimbursement.
My services
Manpower
When short on manpower for building/reviewing economic models, reviewing pharmaco-economic dossiers or for supporting data analysis (max 6 months).
Abraham et al. (2024) Benefits of a digital health technology for elderly nursing home residents. A de-novo cost-effectiveness model of a Digital Health Technology to aid in the assessment of toileting and containment care needs. PLoS ONE.
Abraham, K., & Franken, M. (2023). A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes. Health Policy OPEN, 4, 1-8. Article 100095.
Abraham et al. A BLUEPRINT FOR HTA CAPACITY BUILDING: LESSONS LEARNED FROM MALTA. International Journal of Technology Assessment in Health Care. Accepted Nov 2023 (To be published).
Consultancy
Guiding you through the Dutch reimbursement landscape.
Advising on & building the appropriate health economic models needed for pricing strategies, reimbursement, and investor readiness based on health economics principles.
Publications
Project management
For deliverables, such as pharmaco-economic dossiers/ economic models/ manuscript submissions for which an external project manager is preferred.
Collaborations
Schwengle-Electronics
Erasmus University Rotterdam
Contact Me
Let’s get in contact to find out the needs to make your innovative health technology a success!
You can fill in the form and I will contact you for a first online call or in-person meeting to find out together what the next steps could be.
Alternatively you can send me an message directly to: